1.Li N#, Gou S#, Wang J#, Zhang Q, Huang X, Xie J, Li L, Jin Q, Ouyang Z, Chen F, Ge W, Shi H, Liang Y, Zhuang Z, Zhao X, Lian M, Ye Y, Quan L, Wu H*, Lai L*, Wang K*. CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I. Mol Ther. 2021 Mar 3;29(3):1001-1015.
2. Li W#, Shi L#, Zhuang Z#, Wu H#, Lian M, Chen Y, Li L, Ge W, Jin Q, Zhang Q, Zhao Y, Liu Z, Ouyang Z, Ye Y, Li Y, Wang H, Liao Y, Quan L, Xiao L*, Lai L*, Meng G*, Wang K*. Engineered Pigs Carrying a Gain-of-Function NLRP3 Homozygous Mutation Can Survive to Adulthood and Accurately Recapitulate Human Systemic Spontaneous Inflammatory Responses. J Immunol. 2020 Nov 1;205(9):2532-2544.
3.Lian M#, Chen F#, Huang X#, Zhao X, Gou S, Li N, Jin Q, Shi H, Liang Y, Xie J, Ge W, Zhuang Z, Wang J, Ye Y, Yang Y, Wang K*, Lai L*, Wu H*. Improving the Cpf1-mediated base editing system by combining dCas9/dead sgRNA with human APOBEC3A variants. J Genet Genomics. 2021 Jan 20;48(1):92-95.
4 .Wu H#, Liu Q#, Shi H, Xie J, Zhang Q, Ouyang Z, Li N, Yang Y, Liu Z, Zhao Y, Lai C, Ruan D, Peng J, Ge W, Chen F, Fan N, Jin Q, Liang Y, Lan T, Yang X, Wang X, Lei Z, Doevendans PA, Sluijter JPG, Wang K*, Li X*, Lai L*. Engineering CRISPR/Cpf1 with tRNA promotes genome editing capability in mammalian systems. Cell Mol Life Sci. 2018 Oct;75(19):3593-3607.
5.Yang Y#, Wu H#, Kang X#, Liang Y, Lan T, Li T, Tan T, Peng J, Zhang Q, An G, Liu Y, Yu Q, Ma Z, Lian Y, Soh BS, Chen Q, Liu P, Chen Y, Sun X, Li R, Zhen X, Liu P, Yu Y*, Li X*, Fan Y*. Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs. Protein Cell. 2018 Mar;9(3):283-297.
